Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02988024 · ClinicalTrials.gov registry record · Phase 1

Pilot BA Study of New LY03005 vs Pristiq

A Phase 1 study, sponsored by Luye Pharma Group.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT02988024: Completed Phase 1 study, sponsored by Luye Pharma Group.

NCT02988024 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02988024, a Phase 1 study, has completed, sponsored by Luye Pharma Group.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.

Primary Outcome

PK Samples drawn at 0 (within 30 minutes prior to dosing), 1,2,3,4 (+/- 5 min), 6,8,10,12,23,32,48 and 72 hours (+/- 15 min) after dosing.

Interventions

  • DRUG LY03005
  • DRUG Pristiq

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2016-12-07
Est. Completion 2016-12-28
Phase Phase 1
Luye Pharma Group

22 total trials

What the finished NCT02988024 record still lists

NCT02988024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 2 interventions - of which LY03005 is the first listed.

NCT02988024 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02988024 about?

NCT02988024 is a clinical study titled "Pilot BA Study of New LY03005 vs Pristiq". The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.

What is the current status of trial NCT02988024?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-12-07. Estimated completion is 2016-12-28.

What interventions are being tested in trial NCT02988024?

The interventions under investigation include: LY03005 (DRUG), Pristiq (DRUG).

Who is sponsoring clinical trial NCT02988024?

This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02988024's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02988024, the US trial registry maintained by the National Library of Medicine. NCT02988024 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.